Autor segons l'article: Sanchis, Marta; Capilla, Javier; Castanheira, Mariana; Martin-Vicente, Adela; Sutton, Deanna A; Fothergill, Annette W; Wiederhold, Nathan P; Guarro, Josep
Departament: Ciències Mèdiques Bàsiques
Autor/s de la URV: Capilla Luque, Javier / Guarro Artigas, Josep / Sanchis Talón, Marta
Paraules clau: Voriconazole; Treatment outcome; Resistance; Model; Microbial sensitivity tests; Mice; Mechanisms; Management; Male; Liposomal amphotericin-b; Kidney; Fungal infection; Fluconazole; Fks mutations; Epidemiological cut-off value; Efficacy; Disease models, animal; Combination; Colony count, microbial; Caspofungin; Candidiasis; Candida glabrata; Antifungals; Antifungal agents; Animals; Animal model; fungal infection; epidemiological cut-off value; candida glabrata; antifungals; animal model
Resum: In this study, 27 clinical isolates of Candida glabrata with voriconazole (VRC) minimum inhibitory concentrations (MICs) ranging from ¿0.03 ¿g/mL to 8 ¿g/mL were tested to determine whether in vitro data are predictive of in vivo efficacy. The efficacy of VRC administered at 40 mg/kg was assayed in a neutropenic murine model of disseminated infection by C. glabrata. The reduction in fungal tissue burden in the kidneys was used as a marker of treatment efficacy. VRC reduced the fungal tissue burden in mice infected with strains that had MICs below the epidemiological cut-off value (ECV) of 0.25 ¿g/mL. Variable efficacy of VRC was obtained when the MIC equalled the ECV, and VRC was ineffective when the MIC exceeded the ECV. These results suggest that the use of in vitro data could be useful to predict the outcome for infections by this fungus.
Àrees temàtiques: Saúde coletiva; Química; Pharmacology (medical); Pharmacology & pharmacy; Odontología; Nutrição; Microbiology (medical); Microbiology; Medicine (miscellaneous); Medicina veterinaria; Medicina iii; Medicina ii; Medicina i; Materiais; Interdisciplinar; Infectious diseases; General medicine; Farmacia; Engenharias iii; Engenharias ii; Enfermagem; Ciências biológicas iii; Ciências biológicas ii; Ciências biológicas i; Ciências ambientais; Ciências agrárias i; Biotecnología; Biodiversidade
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 09248579
Adreça de correu electrònic de l'autor: marta.sanchis@urv.cat; javier.capilla@urv.cat
Data d'alta del registre: 2025-01-08
Versió de l'article dipositat: info:eu-repo/semantics/acceptedVersion
Enllaç font original: https://www.sciencedirect.com/science/article/abs/pii/S0924857916000431?via%3Dihub
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: International Journal Of Antimicrobial Agents. 47 (4): 286-288
Referència de l'ítem segons les normes APA: Sanchis, Marta; Capilla, Javier; Castanheira, Mariana; Martin-Vicente, Adela; Sutton, Deanna A; Fothergill, Annette W; Wiederhold, Nathan P; Guarro, J (2016). Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata. International Journal Of Antimicrobial Agents, 47(4), 286-288. DOI: 10.1016/j.ijantimicag.2015.12.020
DOI de l'article: 10.1016/j.ijantimicag.2015.12.020
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2016
Tipus de publicació: Journal Publications
Repositori URV